Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow AZTR by emailGet an email when AZTR pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AZTR, unsubscribe in one click. Privacy
📣 What AZTR Says Is Next
in 2026 · “ATR-12: Netherton syndrome Given the challenges of enrolling patients in this clinical trial and the encouraging safety from the first six enrolled patients in the study, we plan to pause further enrollment of this clinical trial to conserve capital and redirect current funds towards our ATR-COSF program, which has nearer term value creating milestones in 2026.”
Company press release, Jun 17, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full AZTR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AZTR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.